Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
12 - Systemic mast cell disease: diagnosis and management
Published online by Cambridge University Press: 05 March 2016
By
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 97 - 107Publisher: Cambridge University PressPrint publication year: 2016
References
Horny, HP, Metcalfe, DD, Bennett, JM et al. Mastocytosis. In: Swerdlow, SH, Campo, E, Harris, NL et al. (eds) WHO Classification of Tumors of Hematopoetic and Lymphoid Tumours. Lyon: International Agency for Research and Cancer (IARC): 2008;pp. 54–63.Google Scholar
Valent, P, Escribano, L, Broesby-Olsen, S et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014;69(10):1267–74.CrossRefGoogle ScholarPubMed
Sokal, H, Georgin-Lavialle, S, Canioni, D et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol. 2013;132(4):866–73.Google Scholar
Alvares-Twose, I, Gonzalez -de-Olano, D, Sanchez-Munoz, L et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocyosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012;157:275–80. DOI: 10.1159 / 000329856.CrossRefGoogle Scholar
Gulen, T, Hgglund, H, Sander, B et al. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy. 2014;44:1170–87.CrossRefGoogle ScholarPubMed
Nagata, H, Worobec, AS, Oh, CK et al. Identification of a point mutation in the catalytic domain of the proro-oncogene c-kit in the peripheral blood mononuclear cells of patients who have mastocyosis with an associated haematologic disorder. Proc Natl Acad Sci U.S.A. 1995;92:10560–4.CrossRefGoogle Scholar
Akin, C, Fumo, G, Yavuz, AS et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222–5.CrossRefGoogle ScholarPubMed
Tang, X, Boxer, M, Drummond, A et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41;e88.CrossRefGoogle ScholarPubMed
Siebenhaar, F, Degener, F, Krause, K et al. Rupatidine improves quality quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68970:949–52.Google Scholar
Bennett, M, Chubar, Y. Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis. Br J Haematol. 2013;160(4);420.CrossRefGoogle Scholar
Ustun, C, DeRemer, DL, Akin, C. Tyrosine kinase inhibitors in the treatement of systemic mastocytosis. Leuk Res. 2011;35(9):1143–52.CrossRefGoogle Scholar
Theoharides, TC, Boucher, W, Spear, K. Serum interleukin 6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128:344–50.CrossRefGoogle ScholarPubMed
Gulen, T, Hagglund, H, Dahlen, B et al. High prevalence of anaphylaxis in patients with systemic mastocytosis – a single centre experience. Clin Exp Allergy. 2013;44(1):121–9.Google Scholar
Moneret-Vautrin, DA, Morisset, M, Flabbee, J et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy. 2005;60(4):443–51.CrossRefGoogle ScholarPubMed
Valent, P, Akin, C, Sperr, WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46(1):35–48.CrossRefGoogle ScholarPubMed
Pardanani, A, Lim, KH, Lasho, TL et al. Prognostically relevant breakdown of 123 patients with systemic mastocyosis associated with other myeloid malignancies. Blood. 2009;114(18):3769–72.CrossRefGoogle Scholar
Lim, KH, Tefferi, A, Terre, A et al. Systemic mastocytosis in 342 consecutive adults:survival studies and prognostic factors. Blood. 2009;113(23):5727–36.CrossRefGoogle ScholarPubMed
Gotlib, J, Kluin-Nelemans, HC, George, TI et al. Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from a fully accrued global phase 2 CPKC412D2201 trial. 56th ASH Annual meeting, December 6–9 2014. San Francisco, CA. Abstract 634.CrossRefGoogle Scholar
Ustun, C, Reiter, A, Bart, L. Haemopoetic stem cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;3264–74.CrossRefGoogle Scholar
Hauswirth, AW, Simonitsch-Klupp, I, Uffmann, M et al. Response to therapy with interferon-a2b and prednisolone in aggressive systemic mastocytosis; report of 5 cases and review of literature. Leuk Res. 2004;28:249–57.CrossRefGoogle Scholar
Kluin-Nelemans, HC, Butterfield, JH, Hoagkand, HC et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270–6.CrossRefGoogle ScholarPubMed
Hermine, O, Hisrch, I, Damaj, G et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients. ASH Annual Meetings abstracts. Blood. 2010;116:1982.CrossRefGoogle Scholar